GE HealthCare Technologies Inc. (GEHC)

US — Healthcare Sector
Peers: TDOC  VEEV  TXG  PGNY  SDGR  DOCS  AMWL  GDRX 

Automate Your Wheel Strategy on GEHC

With Tiblio's Option Bot, you can configure your own wheel strategy including GEHC - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.

Start Your Free Trial Now

Key Metrics & Ratings

  • symbol GEHC
  • Rev/Share 43.3217
  • Book/Share 20.6083
  • PB 3.5398
  • Debt/Equity 0.9997
  • CurrentRatio 0.9765
  • ROIC 0.0881

 

  • MktCap 32583096600.0
  • FreeCF/Share 3.0066
  • PFCF 23.714
  • PE 14.897
  • Debt/Assets 0.2734
  • DivYield 0.0018
  • ROE 0.2587

 

  • Rating B+
  • Score 3
  • Recommendation Neutral
  • P/E Score 2
  • DCF Score 4
  • P/B Score 2
  • D/E Score 1

Recent Analyst Ratings

Type Ticker Analyst Firm Previous Rating Current Rating Previous Price Target Current Price Target Date
Upgrade GEHC UBS Sell Neutral -- $73 May 5, 2025
Upgrade GEHC Goldman Neutral Buy $85 $100 March 11, 2025
Upgrade GEHC Jefferies Hold Buy $95 $103 Jan. 8, 2025
Downgrade GEHC UBS Neutral Sell $84 $74 Sept. 26, 2024
Upgrade GEHC BTIG Research Neutral Buy -- $100 Sept. 18, 2024
Initiation GEHC JP Morgan -- Neutral -- $90 Sept. 9, 2024

News

GE HealthCare Technologies (GEHC) is a Top-Ranked Value Stock: Should You Buy?
GEHC
Published: February 24, 2025 by: Zacks Investment Research
Sentiment: Positive

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Read More
image for news GE HealthCare Technologies (GEHC) is a Top-Ranked Value Stock: Should You Buy?
GE HealthCare Tops Q4 EPS Forecasts
GEHC
Published: February 13, 2025 by: The Motley Fool
Sentiment: Positive

Medical technology and pharmaceutical diagnostics specialist GE HealthCare Technologies (GEHC -1.30%) reported mixed financial results for the fourth quarter of 2024 on Thursday, Feb. 13. Adjusted earnings per share (EPS) of $1.45 were a significant beat over the anticipated $1.27.

Read More
image for news GE HealthCare Tops Q4 EPS Forecasts
GE HealthCare Technologies (GEHC) Surpasses Q4 Earnings Estimates
GEHC
Published: February 13, 2025 by: Zacks Investment Research
Sentiment: Positive

GE HealthCare Technologies (GEHC) came out with quarterly earnings of $1.45 per share, beating the Zacks Consensus Estimate of $1.26 per share. This compares to earnings of $1.18 per share a year ago.

Read More
image for news GE HealthCare Technologies (GEHC) Surpasses Q4 Earnings Estimates
GE HealthCare forecasts upbeat 2025 profit on steady medical device demand
GEHC
Published: February 13, 2025 by: Reuters
Sentiment: Positive

GE HealthCare Technologies on Thursday forecast annual profit above Wall Street estimates, counting on strong demand for its medical devices in markets such as the U.S. to offset weakness in China.

Read More
image for news GE HealthCare forecasts upbeat 2025 profit on steady medical device demand
GEHC Q4 Earnings: Will Robust Procedures Help Offset Chinese Weakness?
GEHC
Published: February 10, 2025 by: Zacks Investment Research
Sentiment: Positive

GEHC's fourth-quarter results are likely to reflect mixed segmental performance in imaging, advanced visualization solutions and patient care. Pharma is likely to have been the key driver.

Read More
image for news GEHC Q4 Earnings: Will Robust Procedures Help Offset Chinese Weakness?

About GE HealthCare Technologies Inc. (GEHC)

  • IPO Date 2022-12-15
  • Website https://www.gehealthcare.com
  • Industry Medical - Healthcare Information Services
  • CEO Mr. Peter J. Arduini
  • Employees 53000

GE HealthCare Technologies Inc. engages in the development, manufacture, and marketing of products, services, and complementary digital solutions used in the diagnosis, treatment, and monitoring of patients in the United States, Canada, Europe, the Middle East, Africa, China, Taiwan, Mongolia, Hong Kong, and internationally. The company operates through four segments: Imaging, Ultrasound, Patient Care Solutions, and Pharmaceutical Diagnostics. The Imaging segment offers molecular imaging, computed tomography (CT) scanning, magnetic resonance (MR) imaging, image-guided therapy, and X-ray systems, as well as women's health products. The Ultrasound segment provides screening, diagnosis, treatment, and monitoring of certain diseases through radiology and primary care, women's health, cardiovascular, and point of care and handheld ultrasound solutions, as well as surgical visualization and guidance products. The Patient Care Solutions segment involved in the provision of medical devices, consumable products, services, and digital solutions through patient monitoring, anesthesia delivery and respiratory care, diagnostic cardiology, and maternal infant care products. The Pharmaceutical Diagnostics supplies diagnostic agents, including CT, angiography and X-ray, MR, single-photon emission computed tomography, positron emission tomography, and ultrasound to the radiology and nuclear medicine industry. The segment also provides contrast media pharmaceuticals, administered to a patient prior to certain diagnostic scans to increase the visibility of tissues or structures during imaging exams; and molecular imaging agents, or radiopharmaceuticals, which are molecular tracers labeled with radioisotopes that are injected into a patient prior to a diagnostic imaging scan. The company was incorporated in 2022 and is headquartered in Chicago, Illinois.